Sanofi (NASDAQ:SNY) Shares Sold by Altrius Capital Management Inc

Altrius Capital Management Inc cut its stake in shares of Sanofi (NASDAQ:SNY) by 4.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 154,075 shares of the company’s stock after selling 6,658 shares during the quarter. Sanofi accounts for approximately 2.2% of Altrius Capital Management Inc’s holdings, making the stock its 3rd biggest position. Altrius Capital Management Inc’s holdings in Sanofi were worth $8,879,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of SNY. Boston Partners increased its position in shares of Sanofi by 0.3% in the first quarter. Boston Partners now owns 13,066,403 shares of the company’s stock valued at $635,280,000 after buying an additional 33,657 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Sanofi by 19.0% in the second quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock valued at $417,017,000 after buying an additional 1,370,232 shares in the last quarter. Barrow Hanley Mewhinney & Strauss LLC boosted its stake in shares of Sanofi by 113.8% during the second quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock valued at $288,381,000 after acquiring an additional 3,164,092 shares during the last quarter. Envestnet Asset Management Inc. boosted its stake in shares of Sanofi by 8.2% during the second quarter. Envestnet Asset Management Inc. now owns 3,252,326 shares of the company’s stock valued at $157,803,000 after acquiring an additional 246,224 shares during the last quarter. Finally, Federated Hermes Inc. boosted its stake in shares of Sanofi by 26.5% during the second quarter. Federated Hermes Inc. now owns 3,214,141 shares of the company’s stock valued at $155,950,000 after acquiring an additional 673,172 shares during the last quarter. 10.04% of the stock is owned by institutional investors and hedge funds.

Sanofi Stock Performance

NASDAQ SNY traded up $0.15 during midday trading on Friday, hitting $47.97. The company had a trading volume of 789,107 shares, compared to its average volume of 2,025,459. The firm has a fifty day simple moving average of $54.85 and a two-hundred day simple moving average of $52.20. The stock has a market cap of $121.74 billion, a price-to-earnings ratio of 24.40, a P/E/G ratio of 1.26 and a beta of 0.61. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $58.97. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, beating the consensus estimate of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The firm had revenue of $13.44 billion during the quarter, compared to analysts’ expectations of $16.59 billion. During the same quarter last year, the company posted $2.55 EPS. The company’s quarterly revenue was up 12.3% compared to the same quarter last year. Equities analysts forecast that Sanofi will post 4.27 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

SNY has been the topic of a number of research analyst reports. Citigroup raised Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. StockNews.com downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 7th. Finally, Argus boosted their price target on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a report on Friday, July 26th. Two investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.